{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 447570339
| IUPAC_name = 2-[3-[4-(3-chlorophenyl)piperazin-1-yl]propyl]-4,5-diethyl-1,2,4-triazol-3-one
| image = Etoperidone structure.svg
| width = 250px

<!--Clinical data-->
| tradename = Depraser, others
| pregnancy_category = 
| legal_status = 
| routes_of_administration = [[Oral administration|Oral]]

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 52942-31-1
| ATC_prefix = N06
| ATC_suffix = AB09
| PubChem = 40589
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1743259
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 37083
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = KAI6MVO39Z
| synonyms = ST-1191

<!--Chemical data-->
| C=19 | H=28 | Cl=1 | N=5 | O=1 
| molecular_weight = 377.911 g/mol
| SMILES = Clc3cccc(N2CCN(CCCN1/N=C(\N(C1=O)CC)CC)CC2)c3
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C19H28ClN5O/c1-3-18-21-25(19(26)24(18)4-2)10-6-9-22-11-13-23(14-12-22)17-8-5-7-16(20)15-17/h5,7-8,15H,3-4,6,9-14H2,1-2H3
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = IZBNNCFOBMGTQX-UHFFFAOYSA-N
}}

'''Etoperidone''' (brand name '''Depraser''', others) is an [[antidepressant]] which was introduced in 1977 and is no longer marketed.<ref name="IndexNominum2000">{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA421|year=2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|page=421}}</ref><ref name="Publishing2013">{{cite book|author=William Andrew Publishing|title=Pharmaceutical Manufacturing Encyclopedia|url=https://books.google.com/books?id=_J2ti4EkYpkC&pg=PA1533|date=22 October 2013|publisher=Elsevier|isbn=978-0-8155-1856-3|pages=1533–}}</ref><ref name="LamberthDinges2012">{{cite book|author1=Clemens Lamberth|author2=JÃ1⁄4rgen Dinges|title=Bioactive Heterocyclic Compound Classes: Pharmaceuticals|url=https://books.google.com/books?id=35uKnWKD9V8C&pg=RA1-PA50|date=16 August 2012|publisher=John Wiley & Sons|isbn=978-3-527-66447-4|pages=1–}}</ref> It is related to [[trazodone]] and [[nefazodone]] in [[chemical structure]] and is a [[serotonin antagonist and reuptake inhibitor]] (SARI) similarly.<ref name="Morrison-Valfre2016">{{cite book|author=Michelle Morrison-Valfre|title=Foundations of Mental Health Care - E-Book|url=https://books.google.com/books?id=EFfoDAAAQBAJ&pg=PA245|date=23 August 2016|publisher=Elsevier Health Sciences|isbn=978-0-323-37104-9|pages=245–}}</ref>

==Pharmacology==
{| class="wikitable floatleft" style="font-size:small;"
|+ Etoperidone<ref name="PDSP">{{cite web | title = PDSP K<sub>i</sub> Database | work = Psychoactive Drug Screening Program (PDSP) | author1 = Roth, BL | author2 = Driscol, J | publisher = University of North Carolina at Chapel Hill and the United States National Institute of Mental Health | accessdate = 14 August 2017 | url = https://pdsp.unc.edu/databases/pdsp.php?knowID=0&kiKey=&receptorDD=&receptor=&speciesDD=&species=&sourcesDD=&source=&hotLigandDD=&hotLigand=&testLigandDD=&testFreeRadio=testFreeRadio&testLigand=etoperidone&referenceDD=&reference=&KiGreater=&KiLess=&kiAllRadio=all&doQuery=Submit+Query}}</ref>
|-
! Site !! K<sub>i</sub> (nM) !! Species !! Ref
|-
| '''{{abbrlink|SERT|Serotonin transporter}}''' || '''890''' || '''Human''' || <ref name="pmid9537821">{{cite journal | vauthors = Tatsumi M, Groshan K, Blakely RD, Richelson E | title = Pharmacological profile of antidepressants and related compounds at human monoamine transporters | journal = Eur. J. Pharmacol. | volume = 340 | issue = 2-3 | pages = 249–58 | year = 1997 | pmid = 9537821 | doi = | url = }}</ref>
|-
| {{abbrlink|NET|Norepinephrine transporter}} || 20,000 || Human || <ref name="pmid9537821" />
|-
| {{abbrlink|DAT|Dopamine transporter}} || 52,000 || Human || <ref name="pmid9537821" />
|-
| '''[[5-HT1A receptor|5-HT<sub>1A</sub>]]''' || '''85''' || '''Human''' || <ref name="pmid7855217">{{cite journal | vauthors = Cusack B, Nelson A, Richelson E | title = Binding of antidepressants to human brain receptors: focus on newer generation compounds | journal = Psychopharmacology | volume = 114 | issue = 4 | pages = 559–65 | year = 1994 | pmid = 7855217 | doi = | url = }}</ref>
|-
| '''[[5-HT2A receptor|5-HT<sub>2A</sub>]]''' || '''36''' || '''Human''' || <ref name="pmid7855217" />
|-
| [[5-HT2C receptor|5-HT<sub>2C</sub>]] || {{abbr|ND|No data}} || {{abbr|ND|No data}} || {{abbr|ND|No data}}
|-
| '''[[Alpha-1 adrenergic receptor|α<sub>1</sub>]]''' || '''38''' || '''Human''' || <ref name="pmid7855217" />
|-
| '''[[Alpha-2 adrenergic receptor|α<sub>2</sub>]]''' || '''570''' || '''Human''' || <ref name="pmid7855217" />
|-
| [[Dopamine D2 receptor|D<sub>2</sub>]] || 2,300 || Human || <ref name="pmid7855217" />
|-
| [[Histamine H1 receptor|H<sub>1</sub>]] || 3,100 || Human || <ref name="pmid7855217" />
|-
| {{abbrlink|mACh|Muscarinic acetylcholine receptor}} || >35,000 || Human || <ref name="pmid7855217" /><ref name="pmid8100134">{{cite journal | vauthors = Stanton T, Bolden-Watson C, Cusack B, Richelson E | title = Antagonism of the five cloned human muscarinic cholinergic receptors expressed in CHO-K1 cells by antidepressants and antihistaminics | journal = Biochem. Pharmacol. | volume = 45 | issue = 11 | pages = 2352–4 | year = 1993 | pmid = 8100134 | doi = | url = }}</ref>
|- class="sortbottom"
| colspan="4" style="width: 1px;" | Values are K<sub>i</sub> (nM). The smaller the value, the more strongly the drug binds to the site.
|}

Etoperidone is as an [[receptor antagonist|antagonist]] of several [[receptor (biochemistry)|receptors]] in the following order of [[potency (pharmacology)|potency]]: [[5-HT2A receptor|5-HT<sub>2A</sub> receptor]] (36 nM) > [[α1-adrenergic|α<sub>1</sub>-adrenergic receptor]] (38 nM) > [[5-HT1A receptor|5-HT<sub>1A</sub> receptor]] (85 nM) (may be a [[partial agonist]]) > [[α2-adrenergic|α<sub>2</sub>-adrenergic receptor]] (570 nM);<ref name="pmid7855217" /> it has only very weak or negligible [[affinity (pharmacology)|affinity]] for blocking the following receptors: [[D2 receptor|D<sub>2</sub> receptor]] (2,300 nM) > [[H1 receptor|H<sub>1</sub> receptor]] (3,100 nM) > [[muscarinic acetylcholine receptor|mACh receptor]]s (>35,000 nM).<ref name="pmid7855217" /> In addition to its receptor blockade, etoperidone also has weak affinity for the [[monoamine]] [[membrane transport protein|transporter]]s as well: [[serotonin transporter]] (890 nM) > [[norepinephrine transporter]] (20,000 nM) > [[dopamine transporter]] (52,000 nM).<ref name="pmid9537821" />

It is metabolized in part to [[1-(3-Chlorophenyl)piperazine|mCPP]], which probably accounts for its serotonergic effects.<ref name=Garattini>{{cite journal|last1=Garattini|first1=S|title=Active drug metabolites. An overview of their relevance in clinical pharmacokinetics.|journal=Clinical pharmacokinetics|date=1985|volume=10|issue=3|pages=216–27|doi=10.2165/00003088-198510030-00002|pmid=2861928}}</ref><ref>{{cite journal|last1=Raffa|first1=RB|last2=Shank|first2=RP|last3=Vaught|first3=JL|title=Etoperidone, trazodone and MCPP: in vitro and in vivo identification of serotonin 5-HT1A (antagonistic) activity.|journal=Psychopharmacology|date=1992|volume=108|issue=3|pages=320–6|doi=10.1007/BF02245118|pmid=1387963}}</ref>

==Chemistry==
Etoperidone is a [[phenylpiperazine]] and is chemically related to [[nefazodone]] and [[trazodone]].<ref>{{cite book|last1=Akritopoulou-Zanze|first1=Irini|editor1-last=Dinges|editor1-first=Jürgen|editor2-last=Lamberth|editor2-first=Clemens|title=Bioactive heterocyclic compound classes pharmaceuticals|date=2012|publisher=Wiley-VCH|location=Weinheim|isbn=9783527664450|chapter=6. Arylpiperazine-Based 5-HT1A Receptor Partial Agonists and 5-HT2A Antagonists for the Treatment of Autism, Depression, Anxiety, Psychosis, and Schizophrenia}}</ref><ref>{{cite book|editor1-last=Dörwald|editor1-first=Florencioa Zaragoza|title=Lead optimization for medicinal chemists : pharmacokinetic properties of functional groups and organic compounds|date=2012|publisher=Wiley-VCH|location=Weinheim|isbn=9783527645640|chapter=46. Arylalkylamines}}</ref><ref name=DD>{{cite book|last1=Eison|first1=Michael S.|last2=Taylor|first2=Duncan B.|last3=Riblet|first3=Leslie A.|editor1-last=Williams|editor1-first=Michael|editor2-last=Malick|editor2-first=Jeffrey B.|title=Drug Discovery and Development|date=1987|publisher=Springer Science & Business Media|isbn=9781461248286|page=390|url=https://books.google.com/books?id=O0LuBwAAQBAJ&pg=PA390|language=en|chapter=Atypical Psychotropic Agents}}</ref>

==History==
It was discovered by scientists at [[Angelini]], who also discovered trazodone.<ref>{{cite journal|last1=Silvestrini|first1=B|title=Trazodone and the mental pain hypothesis of depression.|journal=Neuropsychobiology|date=1986|volume=15 Suppl 1|pages=2–9|doi=10.1159/000118270|pmid=3014372}}</ref>

Its development name was ST 1191.<ref name="GanellinTriggle1997">{{cite book | author1 = C. R Ganellin | author2 = D. J Triggle | author3 = F.. Macdonald | title = Dictionary of pharmacological agents | url = https://books.google.com/books?id=DeX7jgInYFMC&pg=PA859 | accessdate = 27 November 2011 | year = 1997 | publisher = CRC Press | isbn = 978-0-412-46630-4 | page = 859}}</ref>

The INN name "etoperidone" was proposed in 1976 and recommended in 1977.<ref>{{cite journal|title=Proposed INN List 36|journal=Supplement to the WHO Chronicle|date=1976|volume=30|issue=9|url=https://mednet-communities.net/inn/db/media/docs/p-innlist36.pdf}}</ref><ref>{{cite journal|title=Recommended INN List 17|journal=Supplement to the WHO Chronicle|date=1977|volume=31|issue=10|url=https://mednet-communities.net/inn/db/media/docs/r-innlist17.pdf}}</ref>

It was given brand names in Spain (Centren (Esteve) and Depracer (Lepori)), and was given the brand name Staff by Sigma Tau in Italy<ref name="Index nominum 2000: international drug directory">{{cite book | title = Index nominum 2000: international drug directory | url = https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA421 | accessdate = 27 November 2011 | year = 2000 | publisher = Taylor & Francis US | isbn = 978-3-88763-075-1 | page = 421}}</ref> and was given brand names Axiomin and Etonin,<ref name="GanellinTriggle1997"/> but it is unclear if the drug was marketed; the Pharmaceutical Manufacturing Encyclopedia provides no dates for commercial introduction.<ref>{{cite book|last1=McPherson|first1=Edwin M.|title=Pharmaceutical Manufacturing Encyclopedia.|date=2007|publisher=Elsevier|location=Burlington|isbn=978-0-8155-1856-3|page=1533|edition=3rd ed.}}</ref> According to [[Micromedex]]'s Index Nominum: International Drug Directory, etoperidone was previously marketed in [[Spain]].<ref name="IndexNominum2000" />

==Research==
It has been studied in [[dementia]] and found to be about as effective as [[thioridazine]].<ref>{{cite journal|last1=Kirchner|first1=V|last2=Kelly|first2=CA|last3=Harvey|first3=RJ|title=Thioridazine for dementia.|journal=The Cochrane database of systematic reviews|date=2001|issue=3|pages=CD000464|doi=10.1002/14651858.CD000464|pmid=11686961}}</ref>

==References==
{{Reflist|2}}

{{Antidepressants}}
{{Anxiolytics}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Adrenergic receptor modulators}}
{{Monoamine reuptake inhibitors}}
{{Serotonin receptor modulators}}
}}

[[Category:5-HT2A antagonists]]
[[Category:Abandoned drugs]]
[[Category:Alpha-1 blockers]]
[[Category:Alpha-2 blockers]]
[[Category:Antidepressants]]
[[Category:Anxiolytics]]
[[Category:Chloroarenes]]
[[Category:Lactams]]
[[Category:Piperazines]]
[[Category:Serotonin reuptake inhibitors]]
[[Category:Triazoles]]
[[Category:Ureas]]